These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38986768)

  • 1. Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.
    Rowlands CF; Allen S; Balmaña J; Domchek SM; Evans DG; Hanson H; Hoogerbrugge N; James PA; Nathanson KL; Robson M; Tischkowitz M; Foulkes WD; Turnbull C
    Ann Oncol; 2024 Oct; 35(10):892-901. PubMed ID: 38986768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
    Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
    JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
    Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
    J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
    Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
    Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre.
    Wang X; Waldman L; Silberman Y; Wang M; Tackey C; Hanna L; Vesprini D; Emmenegger U; Eisen A; Smoragiewicz M
    Clin Genitourin Cancer; 2024 Jun; 22(3):102052. PubMed ID: 38461085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
    Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
    Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
    Yadav S; Hu C; Nathanson KL; Weitzel JN; Goldgar DE; Kraft P; Gnanaolivu RD; Na J; Huang H; Boddicker NJ; Larson N; Gao C; Yao S; Weinberg C; Vachon CM; Trentham-Dietz A; Taylor JA; Sandler DR; Patel A; Palmer JR; Olson JE; Neuhausen S; Martinez E; Lindstrom S; Lacey JV; Kurian AW; John EM; Haiman C; Bernstein L; Auer PW; Anton-Culver H; Ambrosone CB; Karam R; Chao E; Yussuf A; Pesaran T; Dolinsky JS; Hart SN; LaDuca H; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Dec; 39(35):3918-3926. PubMed ID: 34672684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
    Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
    Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene.
    Morgan RD; Burghel GJ; Flaum N; Schlecht H; Clamp AR; Hasan J; Mitchell C; Salih Z; Moon S; Hogg M; Lord R; Forde C; Lalloo F; Woodward ER; Crosbie EJ; Taylor SS; Jayson GC; Evans DGR
    Genet Med; 2024 Oct; 26(10):101230. PubMed ID: 39096152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.